HCPCS code J3489: Injection, zoledronic acid, 1 mg

Key Takeaways

HCPCS Code J3489 describes Injection, zoledronic acid, 1 mg – a bisphosphonate infusion used for osteoporosis, bone metastases, hypercalcemia, and Paget’s disease.

Bill J3489 in units matching milligrams administered: 4 units for a 4 mg Zometa dose, 5 units for a 5 mg Reclast dose.

Medicare reimburses J3489 at ASP+6% under the buy-and-bill model; always report the 11-digit NDC alongside the HCPCS code to avoid claim rejection.

Pabau’s claims management software helps infusion practices track drug units, attach NDCs, and apply modifiers JW and JZ before claims go out.

HCPCS Code J3489 is the correct code to report for Injection, zoledronic acid, 1 mg, as maintained by the Centers for Medicare and Medicaid Services (CMS) under the HCPCS Level II system. The code is valid for 2026 and falls under the category “Drugs Administered by Injection” (J0013-J7175).

This guide covers the unit billing calculation, Medicare reimbursement methodology, NDC crosswalk requirements, modifier rules, related codes, and common denial patterns for billing professionals managing claims management software workflows at infusion practices.

HCPCS Code J3489: Description, and clinical context

The most common J3489 billing mistakes trace back to the same root causes: an incorrect unit count, a missing NDC number, or confusion over which code applies now that the older brand-specific codes have been retired. Getting these fundamentals right is what keeps zoledronic acid claims clean.

Clinical indications covered under J3489

Zoledronic acid is a third-generation bisphosphonate administered intravenously. It works by inhibiting osteoclast-mediated bone resorption, making it effective across several oncology and endocrine conditions. The FDA first approved zoledronic acid in 2001.

Medicare coverage under Local Coverage Determination (LCD) L33270 governs which diagnoses support medical necessity for J3489. The primary ICD-10-CM codes that crosswalk to this HCPCS code include:

• M81.0 – Age-related osteoporosis without current pathological fracture
• C79.51 – Secondary malignant neoplasm of bone (bone metastases)
• M88.- – Paget’s disease of bone (osteitis deformans); requires a specific subcategory and site, such as M88.9
• E83.52 – Hypercalcemia

Practices administering zoledronic acid for off-label indications face higher scrutiny. Document the treating physician’s clinical rationale thoroughly before submitting claims tied to diagnoses not listed in LCD L33270. Thorough clinical documentation is the first line of defense against medical necessity denials.

Brand names associated with J3489

Two Novartis brand formulations use zoledronic acid as their active ingredient. Zometa (4 mg/5 mL vial) is indicated for bone metastases and hypercalcemia of malignancy. Reclast (5 mg/100 mL bottle) is indicated for osteoporosis and Paget’s disease. Both are reported under J3489 when using the generic zoledronic acid formulation or when a brand-specific HCPCS code does not otherwise apply.

How to bill J3489: Units, place of service, and modifiers

J3489 is billed per 1 mg of zoledronic acid administered. The unit count on the claim must equal the number of milligrams actually infused. Getting this calculation wrong is the most common source of underpayment and overbilling audits on this code.

Unit calculation by indication

Place of service codes

J3489 is administered across multiple care settings. The place of service (POS) code on the claim affects reimbursement rates and coverage policies.

• POS 11 (Office): Physician office infusion. Reimbursed under the Medicare Physician Fee Schedule at ASP+6%.
• POS 22 (Hospital Outpatient): Administered in a hospital outpatient department. Reimbursed under the Outpatient Prospective Payment System (OPPS), which may package infusion into a bundled payment.
• POS 19 (Off-Campus Outpatient Hospital): Same OPPS rules as POS 22, but the site is not on the main hospital campus. Verify payer-specific policies before billing.

For practices running IV therapy practice management software, the POS code should be configured at the service level, not defaulted to one setting across all infusion visits. Incorrect POS codes are a frequent audit trigger.

Modifier JW and modifier JZ

CMS updated drug waste modifier rules in 2023. Both modifiers apply when a single-dose vial or package is used and some drug is discarded.

• Modifier JW: Append to the line reporting the amount of drug discarded (wasted). Bill the administered dose on one line, the wasted amount on a separate line with JW.
• Modifier JZ: Append to indicate there was no discarded drug (zero waste). Required when the full vial is used. Introduced by CMS to reduce documentation burden when no waste occurs.

Failure to apply the correct modifier triggers claim edits. Automated billing workflows can flag drug-waste modifier requirements at the point of charge capture, reducing manual review time. Using IV therapy intake forms that capture the exact dose drawn and administered also supports accurate modifier application at close of visit.

HCPCS Code J3489 fee schedule and Medicare reimbursement

Medicare Part B reimburses J3489 under the buy-and-bill model at ASP+6% (Average Sales Price plus a 6% add-on). ASP rates are published quarterly by CMS and change with each update. The figures below are directional only; always verify current rates using the CMS Physician Fee Schedule lookup before relying on them for revenue projections.

Because J3489 represents 1 mg, the reimbursable amount per claim scales directly with units billed. A 4-unit claim (4 mg Zometa dose) is reimbursed at 4x the per-unit ASP rate. A 5-unit claim (5 mg Reclast dose) is reimbursed at 5x. This linear relationship makes unit accuracy critical: a single-unit error on a 4 mg dose represents a 25% billing mistake.

Buy-and-bill model implications

Under buy-and-bill, the practice purchases the drug directly, administers it, and then seeks reimbursement from Medicare. The margin between acquisition cost and ASP+6% reimbursement is the practice’s compensation for purchasing, storing, and administering the drug.

When generic zoledronic acid trades below ASP, this margin can be meaningful. When it trades at or above ASP, the economics tighten. IV therapy EMR workflows that integrate drug acquisition cost tracking with billing help practices monitor this margin in real time.

Private payers do not uniformly follow Medicare ASP methodology. Commercial reimbursement for J3489 may be contracted at a percentage of AWP (Average Wholesale Price), a fixed fee schedule, or a negotiated rate. Always confirm the applicable rate in your payer contract before purchasing inventory for non-Medicare patients.

Reduce J3489 claim denials with smarter infusion billing

Pabau's claims management tools help infusion practices track drug units, attach NDCs, apply modifiers, and submit cleaner claims. See how it works in a live demo.

Book a demo

NDC codes and the J3489 crosswalk

Most payers require an 11-digit National Drug Code (NDC) to accompany J3489 on the claim. Without a valid NDC, payers including UnitedHealthcare will reject or deny the claim outright. The NDC must match the specific drug product administered, including manufacturer, package size, and concentration.

NDC numbers are formatted as 5-4-2 on the drug label but must be submitted in 11-digit format on claims (converting to 5-4-2 by zero-filling). Several generic zoledronic acid NDCs crosswalk to J3489.

The UHC NDC maximum units table lists multiple J3489 NDCs with a maximum of 4 units, reflecting the standard Zometa dose. Reclast NDCs submitted with 5 units require specific NDC codes tied to the 5 mg formulation.

Common NDC crosswalk entries for J3489 include formulations from manufacturers such as Avet Pharmaceuticals, Accord Healthcare, and Sun Pharmaceutical, among others. Always verify the specific NDC on the vial label used, as crosswalk lists are updated when manufacturers change packaging. Use the AAPC Codify HCPCS lookup to confirm current NDC-to-HCPCS crosswalk data.

How to report the NDC on the claim form

On CMS-1500 paper claims, the NDC is entered in Box 24 using qualifier N4 before the 11-digit number, followed by the unit of measure qualifier (UN for units) and the quantity. On electronic 837P transactions, the NDC loop (2410) carries the same information.

Most practice management systems allow the NDC to be configured at the drug or service level so it populates automatically. If your system requires manual entry, build a reference card for each zoledronic acid product stocked in your formulary. Auditing NDC accuracy on a sample of claims each month is a sound control against stale-template errors.

J3489 vs J3487, J3488, and J3490: Choosing the right HCPCS code

Several codes sit close to J3489 in the HCPCS J3 group, and two of them are now retired. Knowing which code is current, and which were consolidated into J3489, prevents rejections from billing a deleted code.

The brand-specific codes J3487 (Zometa) and J3488 (Reclast) were retired from Medicare on June 30, 2013 and consolidated into the single generic code J3489. CMS guidance, including the LCD attachment for L33270, directs that J3489 be used to report both Zometa and Reclast.

When in doubt, verify the current code with the specific payer’s billing guidelines, and review related injectable drug procedure code guides for patterns in how payers handle brand-versus-generic distinctions on J-codes.

Common J3489 denial reasons and how to appeal

Zoledronic acid claims have a predictable denial profile. Most billing teams encounter the same four or five denial categories repeatedly. Knowing the root cause of each makes appeals faster and prevents recurrence.

• Missing or invalid NDC: The most common denial reason. The NDC on the claim does not match a known crosswalk for J3489, or the 11-digit format was entered incorrectly. Resolution: resubmit with the correct NDC from the vial label, formatted in 5-4-2 zero-filled 11-digit structure.
• Medical necessity not established: The ICD-10 diagnosis code on the claim is not covered under LCD L33270. Resolution: confirm the diagnosis with the ordering physician and document clinical criteria in the note before appealing.
• Units exceed expected maximum: Some payers set a maximum of 4 units per claim without exception handling for the 5 mg Reclast dose. Resolution: attach clinical documentation showing the 5 mg dose was ordered and administered. Appeal citing payer contract language or coverage policy.
• Prior authorization missing: Commercial payers increasingly require prior authorization for zoledronic acid infusions. Resolution: obtain auth retroactively if the payer allows it, or write off if the auth window has closed. Prevention is the only real solution here, which means building auth verification into the scheduling workflow.
• Wrong place of service: The POS code does not match the actual site of service on record. Resolution: correct and resubmit. POS discrepancies between the claim and the facility’s enrollment record are common during expansions. Mobile IV therapy operations face particular exposure here because the site of service changes with each patient visit.

Building an appeals workflow around these five categories covers the majority of J3489 denial volume. Practices using infusion therapy staffing models where clinical and billing teams are separated should establish a direct escalation path for NDC and medical necessity queries. Delays in those escalations extend the denial-to-cash cycle and age receivables unnecessarily.

For practices still building out their infusion service line, resources on opening an IV therapy practice cover operational infrastructure, including billing team structure, that directly affects claim accuracy from day one. Practices growing into multi-site operations should also confirm that billing configurations scale correctly across locations.

Prior authorization requirements for J3489

Medicare does not currently require prior authorization for J3489, though Medicare Advantage plans operate under individual plan policies that can include auth requirements. Commercial payers vary significantly. UnitedHealthcare, Cigna, Aetna, and BlueCross BlueShield affiliates each maintain their own medical policies for IV bisphosphonate coverage.

The safest workflow is to verify authorization requirements during the scheduling step, not after the infusion is complete. A retroactive auth process is available with some payers but is never guaranteed.

Practices that complete infusions without checking auth status on commercial claims are the most likely to face unrecoverable denials. Digital intake forms that capture insurance information and trigger a verification workflow reduce the window between scheduling and auth confirmation.

For plans that do require prior authorization, the clinical documentation supporting the request should reference the relevant LCD criteria, include the ordering diagnosis, the proposed dose and frequency, and any prior treatment history (such as oral bisphosphonate therapy before escalating to IV). Automating clinic inventory workflows that track drug-dispensing history can also support auth documentation by providing a clear record of doses already administered.

How Pabau supports infusion billing workflows

Infusion billing for J3489 involves multiple touch points: dose verification at administration, NDC capture, modifier assignment, auth tracking, and claim submission. Each step is an opportunity for error when managed across disconnected systems.

Pabau’s claims management software consolidates these workflows. Drug units and NDC codes can be configured at the service level so they pre-populate on each claim. Modifier rules for JW and JZ can be embedded in billing templates. Authorization tracking sits alongside the appointment calendar, making it visible to both clinical and administrative staff before the patient arrives.

Practices managing infusion services alongside other treatments benefit from a single platform that handles scheduling, documentation, and billing without manual data transfer between systems. A connected workflow keeps clinical and billing teams on the same record, which is what keeps charge capture accurate from administration through claim submission.

Conclusion

J3489 billing errors are preventable. The most common denials on this code come from incorrect unit counts, missing NDC numbers, and unverified prior authorizations. Each of those problems has a clear upstream solution in how the service is scheduled, documented, and billed.

Pabau’s claims management tools help infusion practices build those controls directly into their workflow, reducing denials before claims go out rather than chasing them afterward. To see how Pabau handles J3489 and other drug infusion billing workflows, book a demo with the team.

Continue your research

Running an IV therapy service line? IV therapy EMR software from Pabau covers scheduling, clinical documentation, and billing in one platform.

Need guidance on infusion practice operations? infusion therapy best practices covers staffing models, compliance, and workflow setup for infusion providers.

Exploring how to document infusion visits digitally? Pabau’s patient intake forms capture dose, consent, and insurance details before the patient reaches the treatment chair.

Frequently asked questions